A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Trial Profile

A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Grass pollen allergy immunotherapy-BioTech Tools (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors ASIT biotech; BioTech Tools
  • Most Recent Events

    • 12 Mar 2018 According to an ASIT biotech media release, company published new article presenting the results from this study in the scientific journal ALLERGY, the official journal of the European Academy of Allergy and Clinical Immunology (EAACI).
    • 05 Mar 2018 Results evaluating quality of life during hey fever season presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 14 Dec 2017 According to an an ASIT biotech media release, the company reviews and details the results observed in this phase III trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top